Biomerica, Inc. (BMRA) 10-Year Financial Performance & Capital Metrics

BMRA • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentPoint-of-Care Diagnostics

AboutBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Show more

Revenue $5M -1.9%
EBITDA -$5M +21.0%
Net Income -$5M +16.8%
EPS (Diluted) -2.16 -500.0%
Gross Margin 9.38% -16.9%
EBITDA Margin -89.19% +19.4%
Operating Margin -96.72% +17.7%
Net Margin -93.64% +15.2%
ROE -92.99% -42.4%
ROIC -143.49% +5.5%
Debt/Equity 0.11 -6.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 86.3% through buybacks
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.68%

5Y-4.52%

3Y-34.47%

TTM-20.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-105.64%

ROCE

10Y Avg-47.61%

5Y Avg-65.02%

3Y Avg-74.15%

Latest-91.28%

Peer Comparison

Point-of-Care Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
PAVMPAVmed Inc.	8.06M	8.75	17.64	22.15%	-217914.55%	-245.07%
SMLRSemler Scientific, Inc.	310.75M	20.33	3.96	-17.44%	130.8%	10.51%	0.00
BJDXBluejay Diagnostics, Inc.	1.18M	0.65	-0.02			-185.51%	0.04
HSCSHeartSciences Inc.	10.17M	3.20	-0.34	-76.61%	-1042.38%	-216.05%	14.55
LUCDLucid Diagnostics Inc.	163.87M	1.25	-1.19	79%	-8.6%	-404.1%	3.94
BMRABiomerica, Inc.	8.09M	2.68	-1.24	-1.92%	-90.29%	-90.76%	0.11
MDAISpectral AI, Inc.	49.41M	1.61	-1.89	63.83%	-70.64%
CODXCo-Diagnostics, Inc.	6.12M	2.92	-2.35	-42.53%	-63.36%	-80.8%	0.04

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	5.14M	5.79M	5.56M	5.2M	6.69M	7.2M	18.87M	5.34M	5.42M	5.31M
Revenue Growth %	0.04%	0.13%	-0.04%	-0.07%	0.29%	0.08%	1.62%	-0.72%	0.01%	-0.02%
Cost of Goods Sold+	3.62M	3.77M	3.81M	3.91M	4.91M	6.83M	15.89M	4.89M	4.8M	4.81M
COGS % of Revenue	0.7%	0.65%	0.68%	0.75%	0.73%	0.95%	0.84%	0.92%	0.89%	0.91%
Gross Profit+	1.52M	2.02M	1.75M	1.29M	1.78M	366.29K	2.98M	446K	611K	498K
Gross Margin %	0.3%	0.35%	0.32%	0.25%	0.27%	0.05%	0.16%	0.08%	0.11%	0.09%
Gross Profit Growth %	-0.01%	0.33%	-0.13%	-0.26%	0.38%	-0.79%	7.13%	-0.85%	0.37%	-0.18%
Operating Expenses+	2.35M	2.98M	3.24M	3.7M	4.18M	7.87M	7.51M	7.67M	6.98M	5.63M
OpEx % of Revenue	0.46%	0.51%	0.58%	0.71%	0.63%	1.09%	0.4%	1.44%	1.29%	1.06%
Selling, General & Admin	1.57M	1.85M	1.84M	2.03M	2.27M	5.67M	5.7M	6.08M	5.49M	4.61M
SG&A % of Revenue	0.31%	0.32%	0.33%	0.39%	0.34%	0.79%	0.3%	1.14%	1.01%	0.87%
Research & Development	780.33K	1.13M	1.4M	1.68M	1.91M	2.19M	1.81M	1.58M	1.49M	1.02M
R&D % of Revenue	0.15%	0.2%	0.25%	0.32%	0.29%	0.3%	0.1%	0.3%	0.28%	0.19%
Other Operating Expenses	7.01K	0	0	0	0	0	0	1K	0	0
Operating Income+	-826.95K	-954.63K	-1.48M	-2.41M	-2.4M	-7.5M	-4.53M	-7.22M	-6.37M	-5.14M
Operating Margin %	-0.16%	-0.16%	-0.27%	-0.46%	-0.36%	-1.04%	-0.24%	-1.35%	-1.18%	-0.97%
Operating Income Growth %	-0.23%	-0.15%	-0.55%	-0.63%	0%	-2.12%	0.4%	-0.59%	0.12%	0.19%
EBITDA+	-594.53K	-735.41K	-1.3M	-2.25M	-2M	-7.12M	-3.94M	-6.87M	-5.99M	-4.74M
EBITDA Margin %	-0.12%	-0.13%	-0.23%	-0.43%	-0.3%	-0.99%	-0.21%	-1.29%	-1.11%	-0.89%
EBITDA Growth %	-0.42%	-0.24%	-0.76%	-0.74%	0.11%	-2.55%	0.45%	-0.74%	0.13%	0.21%
D&A (Non-Cash Add-back)	232.42K	219.22K	186.6K	162.91K	398.63K	375.86K	594.82K	351K	374K	400K
EBIT	-795.82K	-908.28K	-1.43M	-2.37M	-2.33M	-7.43M	-4.53M	-7.22M	-6.37M	-5.14M
Net Interest Income+	23.96K	46.07K	47.73K	43.97K	71.18K	66.5K	27K	133K	431K	165K
Interest Income	24.12K	46.35K	47.76K	44.01K	71.19K	66.86K	27K	133K	431K	165K
Interest Expense	167	282	37	47	9	367	0	0	0	0
Other Income/Expense	30.96K	46.07K	47.73K	43.97K	71.18K	66.5K	26.64K	134K	431K	165K
Pretax Income+	-795.99K	-908.56K	-1.43M	-2.37M	-2.33M	-7.43M	-4.51M	-7.09M	-5.94M	-4.97M
Pretax Margin %	-0.15%	-0.16%	-0.26%	-0.46%	-0.35%	-1.03%	-0.24%	-1.33%	-1.1%	-0.94%
Income Tax+	703.8K	0	31.8K	24.24K	7.39K	13.06K	23.72K	51K	42K	1K
Effective Tax Rate %	1.88%	1%	1.02%	1.01%	1%	1%	1.01%	1.01%	1.01%	1%
Net Income+	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Net Margin %	-0.29%	-0.16%	-0.26%	-0.46%	-0.35%	-1.03%	-0.24%	-1.34%	-1.1%	-0.94%
Net Income Growth %	-3.53%	0.39%	-0.61%	-0.63%	0.02%	-2.18%	0.39%	-0.58%	0.16%	0.17%
Net Income (Continuing)	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.20	-0.11	-0.17	-0.26	-0.23	-0.54	-0.36	-0.50	-0.36	-2.16
EPS Growth %	-3.56%	0.45%	-0.55%	-0.53%	0.12%	-1.35%	0.33%	-0.39%	0.28%	-5%
EPS (Basic)	-0.20	-0.11	-0.17	-0.26	-0.23	-0.54	-0.36	-0.50	-0.36	-2.16
Diluted Shares Outstanding	7.63M	8.33M	8.57M	9.21M	10.17M	11.93M	12.67M	14.15M	16.82M	2.3M
Basic Shares Outstanding	7.5M	8.26M	8.57M	9.21M	10.17M	11.93M	12.67M	14.15M	16.82M	2.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	4.84M	4.21M	4.48M	4.49M	14.77M	9.23M	9.43M	12.8M	7.73M	4.88M
Cash & Short-Term Investments	1.89M	1.23M	1.2M	686.78K	8.64M	4.2M	5.92M	9.72M	4.17M	2.4M
Cash Only	1.89M	1.23M	1.2M	686.78K	8.64M	4.2M	5.92M	9.72M	4.17M	2.4M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	969.47K	1.06M	799.94K	1.45M	1.77M	1.46M	773.82K	722K	947K	731K
Days Sales Outstanding	68.85	66.8	52.47	102.09	96.31	73.77	14.97	49.36	63.83	50.24
Inventory	1.86M	1.73M	2.18M	2.15M	2.85M	3.21M	2.42M	2.06M	2.38M	1.49M
Days Inventory Outstanding	188.07	167.41	208.74	200.87	211.89	171.26	55.48	153.37	180.52	113
Other Current Assets	113.58K	195.76K	300.41K	202.4K	0	0	447	0	0	255K
Total Non-Current Assets+	891.44K	807.64K	738.55K	750.43K	2.49M	2.59M	1.95M	1.66M	1.52M	1.07M
Property, Plant & Equipment	380.66K	331.86K	351.15K	351.07K	1.99M	1.86M	1.52M	1.25M	943K	564K
Fixed Asset Turnover	13.50x	17.45x	15.85x	14.81x	3.36x	3.86x	12.45x	4.28x	5.74x	9.42x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	248.8K	174.47K	98.92K	107.21K	168.66K	294.83K	170K	165K	212K	228K
Long-Term Investments	165.32K	165.32K	165.32K	165.32K	165.32K	165.32K	165.32K	165K	165K	165K
Other Non-Current Assets	55.65K	94.99K	113.16K	126.83K	168.19K	264.15K	95.59K	79K	203K	113K
Total Assets+	5.73M	5.02M	5.22M	5.25M	17.26M	11.82M	11.37M	14.45M	9.25M	5.95M
Asset Turnover	0.90x	1.15x	1.07x	0.99x	0.39x	0.61x	1.66x	0.37x	0.59x	0.89x
Asset Growth %	-0.06%	-0.12%	0.04%	0%	2.29%	-0.32%	-0.04%	0.27%	-0.36%	-0.36%
Total Current Liabilities+	506.03K	528.87K	896.81K	1.26M	1.48M	1.3M	2.01M	1.95M	2.2M	1.74M
Accounts Payable	325.98K	336.43K	655.6K	999.59K	833.41K	431K	736K	344K	288K	295K
Days Payables Outstanding	32.91	32.57	62.81	93.34	61.94	23.02	16.9	25.66	21.88	22.37
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	51K	60K	85K	55K
Other Current Liabilities	7.5K	15.57K	31.36K	37.97K	0	389.28K	282	0	655K	655K
Current Ratio	9.55x	7.96x	5.00x	3.56x	10.00x	7.10x	4.69x	6.58x	3.51x	2.80x
Quick Ratio	5.87x	4.69x	2.57x	1.85x	8.07x	4.63x	3.49x	5.52x	2.43x	1.95x
Cash Conversion Cycle	224.01	201.64	198.4	209.62	246.25	222.01	53.55	177.07	222.48	140.86
Total Non-Current Liabilities+	0	8K	0	999.59K	1.57M	1.29M	1.04M	785K	459K	100K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.57M	1.29M	1.04M	785K	459K	100K
Deferred Tax Liabilities	0	8K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	-8K	0	0	0	0	284	0	0	0
Total Liabilities	506.03K	528.87K	896.81K	1.26M	3.05M	2.59M	3.05M	2.73M	2.66M	1.84M
Total Debt+	0	0	0	0	1.78M	1.62M	1.38M	1.08M	785K	458K
Net Debt	-1.89M	-1.23M	-1.2M	-686.78K	-6.86M	-2.58M	-4.54M	-8.64M	-3.38M	-1.94M
Debt / Equity	-	-	-	-	0.13x	0.18x	0.17x	0.09x	0.12x	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4951.81x	-3385.22x	-40047.43x	-51335.96x	-266983.11x	-20435.13x	-	-	-	-
Total Equity+	5.22M	4.49M	4.33M	3.98M	14.21M	9.23M	8.32M	11.72M	6.59M	4.11M
Equity Growth %	-0.07%	-0.14%	-0.04%	-0.08%	2.57%	-0.35%	-0.1%	0.41%	-0.44%	-0.38%
Book Value per Share	0.68	0.54	0.50	0.43	1.40	0.77	0.66	0.83	0.39	1.79
Total Shareholders' Equity	5.22M	4.49M	4.33M	3.98M	14.21M	9.23M	8.32M	11.72M	6.59M	4.11M
Common Stock	653.57K	680.89K	711.04K	774.17K	939.21K	984.57K	1.03M	1.35M	1.35M	203K
Retained Earnings	-14.82M	-15.73M	-17.19M	-19.59M	-21.93M	-30.55M	-35.08M	-42.22M	-48.2M	-53.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-13.59K	-15.83K	-26.14K	-36.53K	-39.84K	-47.96K	-73.94K	-110K	-102K	-105K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	-208.78K	-722.86K	-1.17M	-2.24M	-4.3M	-5.25M	-480.53K	-5.47M	-5.36M	-3.84M
Operating CF Margin %	-0.04%	-0.12%	-0.21%	-0.43%	-0.64%	-0.73%	-0.03%	-1.03%	-0.99%	-0.72%
Operating CF Growth %	0.49%	-2.46%	-0.62%	-0.91%	-0.92%	-0.22%	0.91%	-10.39%	0.02%	0.28%
Net Income	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Depreciation & Amortization	232.42K	219.22K	186.6K	162.91K	398.63K	375.86K	594.82K	351K	374K	400K
Stock-Based Compensation	15.15K	21.73K	18.47K	151.22K	200.47K	0	1.26M	1.19M	837K	460K
Deferred Taxes	703K	-16.5K	31K	10K	0	0	0	0	0	0
Other Non-Cash Items	-923	8.07K	23.4K	12.91K	-37.97K	3.67M	-719.15K	168K	31K	4K
Working Capital Changes	341.35K	-46.81K	32.14K	-188.02K	-2.54M	-1.85M	2.91M	-38K	-625K	268K
Change in Receivables	151.16K	-132.26K	252.5K	-670.13K	-309.09K	-455.61K	1.37M	-291K	-215K	209K
Change in Inventory	137.13K	150.47K	-457.27K	21.39K	-717.46K	-1.91M	1.56M	534K	-115K	882K
Change in Payables	-30.58K	10.45K	319.17K	343.99K	-12.88K	-403.33K	-403.33K	-80K	246K	-466K
Cash from Investing+	-95.19K	-96.08K	-130.35K	-171.11K	-118.93K	-295.58K	-170.34K	-78K	-115K	-37K
Capital Expenditures	-95.19K	-96.08K	-130.35K	-171.11K	-118.93K	-295.58K	-170.34K	-78K	-51K	-37K
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.02%	0.04%	0.01%	0.01%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	-64K	0
Cash from Financing+	1.11M	157.73K	1.29M	1.91M	12.37M	1.11M	2.39M	9.39M	-81K	2.11M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	109.94K	0	27.44K	130.85K	223.53K	102.25K	77.52K	81K	0	-32K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-303.97K	-818.94K	-1.3M	-2.42M	-4.42M	-5.55M	-650.87K	-5.55M	-5.48M	-3.88M
FCF Margin %	-0.06%	-0.14%	-0.23%	-0.46%	-0.66%	-0.77%	-0.03%	-1.04%	-1.01%	-0.73%
FCF Growth %	0.29%	-1.69%	-0.59%	-0.85%	-0.83%	-0.26%	0.88%	-7.53%	0.01%	0.29%
FCF per Share	-0.04	-0.10	-0.15	-0.26	-0.43	-0.47	-0.05	-0.39	-0.33	-1.69
FCF Conversion (FCF/Net Income)	0.14x	0.80x	0.80x	0.94x	1.84x	0.71x	0.11x	0.77x	0.90x	0.77x
Interest Paid	167	282	37	47	9	367	0	0	0	0
Taxes Paid	-800	800	800	14.24K	7.39K	27.17K	24K	51K	41K	10K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-27.72%	-18.71%	-33.26%	-57.62%	-25.71%	-63.53%	-51.63%	-71.23%	-65.28%	-92.99%
Return on Invested Capital (ROIC)	-15.81%	-21.71%	-34.81%	-56.42%	-33.85%	-80.35%	-65.18%	-157.61%	-151.76%	-143.49%
Gross Margin	29.65%	34.91%	31.53%	24.84%	26.62%	5.09%	15.78%	8.35%	11.28%	9.38%
Net Margin	-29.18%	-15.69%	-26.34%	-46.01%	-34.95%	-103.43%	-24.01%	-133.73%	-110.4%	-93.64%
Debt / Equity	-	-	-	-	0.13x	0.18x	0.17x	0.09x	0.12x	0.11x
Interest Coverage	-4951.81x	-3385.22x	-40047.43x	-51335.96x	-266983.11x	-20435.13x	-	-	-	-
FCF Conversion	0.14x	0.80x	0.80x	0.94x	1.84x	0.71x	0.11x	0.77x	0.90x	0.77x
Revenue Growth	3.58%	12.68%	-3.93%	-6.53%	28.69%	7.57%	162.14%	-71.71%	1.42%	-1.92%

Revenue by Segment

	2020	2021	2025
ClinicalLabMember	2.92M	3.08M	-
ClinicalLabMember Growth	-	5.29%	-
PhysiciansOfficeMember	2.19M	2.8M	-
PhysiciansOfficeMember Growth	-	27.61%	-
OverthecounterMember	-	766K	-
OverthecounterMember Growth	-	-	-
ContractManufacturingMember	305.76K	552K	-
ContractManufacturingMember Growth	-	80.53%	-
LabSuppliesMember	-	3K	-
LabSuppliesMember Growth	-	-	-
OTCMember	1.27M	-	-
OTCMember Growth	-	-	-

Revenue by Geography

	2020	2021	2025
Asia	-	-	1.72M
Asia Growth	-	-	-
North America	-	-	1.66M
North America Growth	-	-	-
Europe	-	-	1.3M
Europe Growth	-	-	-
Middle East	-	-	630K
Middle East Growth	-	-	-
South America	-	-	8K
South America Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Biomerica, Inc. (BMRA) reported $4.5M in revenue for fiscal year 2025. This represents a 27% decrease from $6.1M in 2012.

Biomerica, Inc. (BMRA) saw revenue decline by 1.9% over the past year.

Biomerica, Inc. (BMRA) reported a net loss of $4.0M for fiscal year 2025.

Dividend & Returns

Biomerica, Inc. (BMRA) has a return on equity (ROE) of -93.0%. Negative ROE indicates the company is unprofitable.

Biomerica, Inc. (BMRA) had negative free cash flow of $2.9M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Biomerica, Inc. (BMRA) 10-Year Financial Performance & Capital Metrics

BMRA • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentPoint-of-Care Diagnostics

Revenue $5M -1.9%
EBITDA -$5M +21.0%
Net Income -$5M +16.8%
EPS (Diluted) -2.16 -500.0%
Gross Margin 9.38% -16.9%
EBITDA Margin -89.19% +19.4%
Operating Margin -96.72% +17.7%
Net Margin -93.64% +15.2%
ROE -92.99% -42.4%
ROIC -143.49% +5.5%
Debt/Equity 0.11 -6.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 86.3% through buybacks
✓Trading at only 1.5x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.68%

5Y-4.52%

3Y-34.47%

TTM-20.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-105.64%

ROCE

10Y Avg-47.61%

5Y Avg-65.02%

3Y Avg-74.15%

Latest-91.28%

Peer Comparison

Point-of-Care Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
PAVMPAVmed Inc.	8.06M	8.75	17.64	22.15%	-217914.55%	-245.07%
SMLRSemler Scientific, Inc.	310.75M	20.33	3.96	-17.44%	130.8%	10.51%	0.00
BJDXBluejay Diagnostics, Inc.	1.18M	0.65	-0.02			-185.51%	0.04
HSCSHeartSciences Inc.	10.17M	3.20	-0.34	-76.61%	-1042.38%	-216.05%	14.55
LUCDLucid Diagnostics Inc.	163.87M	1.25	-1.19	79%	-8.6%	-404.1%	3.94
BMRABiomerica, Inc.	8.09M	2.68	-1.24	-1.92%	-90.29%	-90.76%	0.11
MDAISpectral AI, Inc.	49.41M	1.61	-1.89	63.83%	-70.64%
CODXCo-Diagnostics, Inc.	6.12M	2.92	-2.35	-42.53%	-63.36%	-80.8%	0.04

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	5.14M	5.79M	5.56M	5.2M	6.69M	7.2M	18.87M	5.34M	5.42M	5.31M
Revenue Growth %	0.04%	0.13%	-0.04%	-0.07%	0.29%	0.08%	1.62%	-0.72%	0.01%	-0.02%
Cost of Goods Sold+	3.62M	3.77M	3.81M	3.91M	4.91M	6.83M	15.89M	4.89M	4.8M	4.81M
COGS % of Revenue	0.7%	0.65%	0.68%	0.75%	0.73%	0.95%	0.84%	0.92%	0.89%	0.91%
Gross Profit+	1.52M	2.02M	1.75M	1.29M	1.78M	366.29K	2.98M	446K	611K	498K
Gross Margin %	0.3%	0.35%	0.32%	0.25%	0.27%	0.05%	0.16%	0.08%	0.11%	0.09%
Gross Profit Growth %	-0.01%	0.33%	-0.13%	-0.26%	0.38%	-0.79%	7.13%	-0.85%	0.37%	-0.18%
Operating Expenses+	2.35M	2.98M	3.24M	3.7M	4.18M	7.87M	7.51M	7.67M	6.98M	5.63M
OpEx % of Revenue	0.46%	0.51%	0.58%	0.71%	0.63%	1.09%	0.4%	1.44%	1.29%	1.06%
Selling, General & Admin	1.57M	1.85M	1.84M	2.03M	2.27M	5.67M	5.7M	6.08M	5.49M	4.61M
SG&A % of Revenue	0.31%	0.32%	0.33%	0.39%	0.34%	0.79%	0.3%	1.14%	1.01%	0.87%
Research & Development	780.33K	1.13M	1.4M	1.68M	1.91M	2.19M	1.81M	1.58M	1.49M	1.02M
R&D % of Revenue	0.15%	0.2%	0.25%	0.32%	0.29%	0.3%	0.1%	0.3%	0.28%	0.19%
Other Operating Expenses	7.01K	0	0	0	0	0	0	1K	0	0
Operating Income+	-826.95K	-954.63K	-1.48M	-2.41M	-2.4M	-7.5M	-4.53M	-7.22M	-6.37M	-5.14M
Operating Margin %	-0.16%	-0.16%	-0.27%	-0.46%	-0.36%	-1.04%	-0.24%	-1.35%	-1.18%	-0.97%
Operating Income Growth %	-0.23%	-0.15%	-0.55%	-0.63%	0%	-2.12%	0.4%	-0.59%	0.12%	0.19%
EBITDA+	-594.53K	-735.41K	-1.3M	-2.25M	-2M	-7.12M	-3.94M	-6.87M	-5.99M	-4.74M
EBITDA Margin %	-0.12%	-0.13%	-0.23%	-0.43%	-0.3%	-0.99%	-0.21%	-1.29%	-1.11%	-0.89%
EBITDA Growth %	-0.42%	-0.24%	-0.76%	-0.74%	0.11%	-2.55%	0.45%	-0.74%	0.13%	0.21%
D&A (Non-Cash Add-back)	232.42K	219.22K	186.6K	162.91K	398.63K	375.86K	594.82K	351K	374K	400K
EBIT	-795.82K	-908.28K	-1.43M	-2.37M	-2.33M	-7.43M	-4.53M	-7.22M	-6.37M	-5.14M
Net Interest Income+	23.96K	46.07K	47.73K	43.97K	71.18K	66.5K	27K	133K	431K	165K
Interest Income	24.12K	46.35K	47.76K	44.01K	71.19K	66.86K	27K	133K	431K	165K
Interest Expense	167	282	37	47	9	367	0	0	0	0
Other Income/Expense	30.96K	46.07K	47.73K	43.97K	71.18K	66.5K	26.64K	134K	431K	165K
Pretax Income+	-795.99K	-908.56K	-1.43M	-2.37M	-2.33M	-7.43M	-4.51M	-7.09M	-5.94M	-4.97M
Pretax Margin %	-0.15%	-0.16%	-0.26%	-0.46%	-0.35%	-1.03%	-0.24%	-1.33%	-1.1%	-0.94%
Income Tax+	703.8K	0	31.8K	24.24K	7.39K	13.06K	23.72K	51K	42K	1K
Effective Tax Rate %	1.88%	1%	1.02%	1.01%	1%	1%	1.01%	1.01%	1.01%	1%
Net Income+	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Net Margin %	-0.29%	-0.16%	-0.26%	-0.46%	-0.35%	-1.03%	-0.24%	-1.34%	-1.1%	-0.94%
Net Income Growth %	-3.53%	0.39%	-0.61%	-0.63%	0.02%	-2.18%	0.39%	-0.58%	0.16%	0.17%
Net Income (Continuing)	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.20	-0.11	-0.17	-0.26	-0.23	-0.54	-0.36	-0.50	-0.36	-2.16
EPS Growth %	-3.56%	0.45%	-0.55%	-0.53%	0.12%	-1.35%	0.33%	-0.39%	0.28%	-5%
EPS (Basic)	-0.20	-0.11	-0.17	-0.26	-0.23	-0.54	-0.36	-0.50	-0.36	-2.16
Diluted Shares Outstanding	7.63M	8.33M	8.57M	9.21M	10.17M	11.93M	12.67M	14.15M	16.82M	2.3M
Basic Shares Outstanding	7.5M	8.26M	8.57M	9.21M	10.17M	11.93M	12.67M	14.15M	16.82M	2.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	4.84M	4.21M	4.48M	4.49M	14.77M	9.23M	9.43M	12.8M	7.73M	4.88M
Cash & Short-Term Investments	1.89M	1.23M	1.2M	686.78K	8.64M	4.2M	5.92M	9.72M	4.17M	2.4M
Cash Only	1.89M	1.23M	1.2M	686.78K	8.64M	4.2M	5.92M	9.72M	4.17M	2.4M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	969.47K	1.06M	799.94K	1.45M	1.77M	1.46M	773.82K	722K	947K	731K
Days Sales Outstanding	68.85	66.8	52.47	102.09	96.31	73.77	14.97	49.36	63.83	50.24
Inventory	1.86M	1.73M	2.18M	2.15M	2.85M	3.21M	2.42M	2.06M	2.38M	1.49M
Days Inventory Outstanding	188.07	167.41	208.74	200.87	211.89	171.26	55.48	153.37	180.52	113
Other Current Assets	113.58K	195.76K	300.41K	202.4K	0	0	447	0	0	255K
Total Non-Current Assets+	891.44K	807.64K	738.55K	750.43K	2.49M	2.59M	1.95M	1.66M	1.52M	1.07M
Property, Plant & Equipment	380.66K	331.86K	351.15K	351.07K	1.99M	1.86M	1.52M	1.25M	943K	564K
Fixed Asset Turnover	13.50x	17.45x	15.85x	14.81x	3.36x	3.86x	12.45x	4.28x	5.74x	9.42x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	248.8K	174.47K	98.92K	107.21K	168.66K	294.83K	170K	165K	212K	228K
Long-Term Investments	165.32K	165.32K	165.32K	165.32K	165.32K	165.32K	165.32K	165K	165K	165K
Other Non-Current Assets	55.65K	94.99K	113.16K	126.83K	168.19K	264.15K	95.59K	79K	203K	113K
Total Assets+	5.73M	5.02M	5.22M	5.25M	17.26M	11.82M	11.37M	14.45M	9.25M	5.95M
Asset Turnover	0.90x	1.15x	1.07x	0.99x	0.39x	0.61x	1.66x	0.37x	0.59x	0.89x
Asset Growth %	-0.06%	-0.12%	0.04%	0%	2.29%	-0.32%	-0.04%	0.27%	-0.36%	-0.36%
Total Current Liabilities+	506.03K	528.87K	896.81K	1.26M	1.48M	1.3M	2.01M	1.95M	2.2M	1.74M
Accounts Payable	325.98K	336.43K	655.6K	999.59K	833.41K	431K	736K	344K	288K	295K
Days Payables Outstanding	32.91	32.57	62.81	93.34	61.94	23.02	16.9	25.66	21.88	22.37
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	51K	60K	85K	55K
Other Current Liabilities	7.5K	15.57K	31.36K	37.97K	0	389.28K	282	0	655K	655K
Current Ratio	9.55x	7.96x	5.00x	3.56x	10.00x	7.10x	4.69x	6.58x	3.51x	2.80x
Quick Ratio	5.87x	4.69x	2.57x	1.85x	8.07x	4.63x	3.49x	5.52x	2.43x	1.95x
Cash Conversion Cycle	224.01	201.64	198.4	209.62	246.25	222.01	53.55	177.07	222.48	140.86
Total Non-Current Liabilities+	0	8K	0	999.59K	1.57M	1.29M	1.04M	785K	459K	100K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.57M	1.29M	1.04M	785K	459K	100K
Deferred Tax Liabilities	0	8K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	-8K	0	0	0	0	284	0	0	0
Total Liabilities	506.03K	528.87K	896.81K	1.26M	3.05M	2.59M	3.05M	2.73M	2.66M	1.84M
Total Debt+	0	0	0	0	1.78M	1.62M	1.38M	1.08M	785K	458K
Net Debt	-1.89M	-1.23M	-1.2M	-686.78K	-6.86M	-2.58M	-4.54M	-8.64M	-3.38M	-1.94M
Debt / Equity	-	-	-	-	0.13x	0.18x	0.17x	0.09x	0.12x	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-4951.81x	-3385.22x	-40047.43x	-51335.96x	-266983.11x	-20435.13x	-	-	-	-
Total Equity+	5.22M	4.49M	4.33M	3.98M	14.21M	9.23M	8.32M	11.72M	6.59M	4.11M
Equity Growth %	-0.07%	-0.14%	-0.04%	-0.08%	2.57%	-0.35%	-0.1%	0.41%	-0.44%	-0.38%
Book Value per Share	0.68	0.54	0.50	0.43	1.40	0.77	0.66	0.83	0.39	1.79
Total Shareholders' Equity	5.22M	4.49M	4.33M	3.98M	14.21M	9.23M	8.32M	11.72M	6.59M	4.11M
Common Stock	653.57K	680.89K	711.04K	774.17K	939.21K	984.57K	1.03M	1.35M	1.35M	203K
Retained Earnings	-14.82M	-15.73M	-17.19M	-19.59M	-21.93M	-30.55M	-35.08M	-42.22M	-48.2M	-53.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-13.59K	-15.83K	-26.14K	-36.53K	-39.84K	-47.96K	-73.94K	-110K	-102K	-105K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	-208.78K	-722.86K	-1.17M	-2.24M	-4.3M	-5.25M	-480.53K	-5.47M	-5.36M	-3.84M
Operating CF Margin %	-0.04%	-0.12%	-0.21%	-0.43%	-0.64%	-0.73%	-0.03%	-1.03%	-0.99%	-0.72%
Operating CF Growth %	0.49%	-2.46%	-0.62%	-0.91%	-0.92%	-0.22%	0.91%	-10.39%	0.02%	0.28%
Net Income	-1.5M	-908.56K	-1.47M	-2.39M	-2.34M	-7.45M	-4.53M	-7.14M	-5.98M	-4.97M
Depreciation & Amortization	232.42K	219.22K	186.6K	162.91K	398.63K	375.86K	594.82K	351K	374K	400K
Stock-Based Compensation	15.15K	21.73K	18.47K	151.22K	200.47K	0	1.26M	1.19M	837K	460K
Deferred Taxes	703K	-16.5K	31K	10K	0	0	0	0	0	0
Other Non-Cash Items	-923	8.07K	23.4K	12.91K	-37.97K	3.67M	-719.15K	168K	31K	4K
Working Capital Changes	341.35K	-46.81K	32.14K	-188.02K	-2.54M	-1.85M	2.91M	-38K	-625K	268K
Change in Receivables	151.16K	-132.26K	252.5K	-670.13K	-309.09K	-455.61K	1.37M	-291K	-215K	209K
Change in Inventory	137.13K	150.47K	-457.27K	21.39K	-717.46K	-1.91M	1.56M	534K	-115K	882K
Change in Payables	-30.58K	10.45K	319.17K	343.99K	-12.88K	-403.33K	-403.33K	-80K	246K	-466K
Cash from Investing+	-95.19K	-96.08K	-130.35K	-171.11K	-118.93K	-295.58K	-170.34K	-78K	-115K	-37K
Capital Expenditures	-95.19K	-96.08K	-130.35K	-171.11K	-118.93K	-295.58K	-170.34K	-78K	-51K	-37K
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.02%	0.04%	0.01%	0.01%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	-64K	0
Cash from Financing+	1.11M	157.73K	1.29M	1.91M	12.37M	1.11M	2.39M	9.39M	-81K	2.11M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	109.94K	0	27.44K	130.85K	223.53K	102.25K	77.52K	81K	0	-32K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-303.97K	-818.94K	-1.3M	-2.42M	-4.42M	-5.55M	-650.87K	-5.55M	-5.48M	-3.88M
FCF Margin %	-0.06%	-0.14%	-0.23%	-0.46%	-0.66%	-0.77%	-0.03%	-1.04%	-1.01%	-0.73%
FCF Growth %	0.29%	-1.69%	-0.59%	-0.85%	-0.83%	-0.26%	0.88%	-7.53%	0.01%	0.29%
FCF per Share	-0.04	-0.10	-0.15	-0.26	-0.43	-0.47	-0.05	-0.39	-0.33	-1.69
FCF Conversion (FCF/Net Income)	0.14x	0.80x	0.80x	0.94x	1.84x	0.71x	0.11x	0.77x	0.90x	0.77x
Interest Paid	167	282	37	47	9	367	0	0	0	0
Taxes Paid	-800	800	800	14.24K	7.39K	27.17K	24K	51K	41K	10K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-27.72%	-18.71%	-33.26%	-57.62%	-25.71%	-63.53%	-51.63%	-71.23%	-65.28%	-92.99%
Return on Invested Capital (ROIC)	-15.81%	-21.71%	-34.81%	-56.42%	-33.85%	-80.35%	-65.18%	-157.61%	-151.76%	-143.49%
Gross Margin	29.65%	34.91%	31.53%	24.84%	26.62%	5.09%	15.78%	8.35%	11.28%	9.38%
Net Margin	-29.18%	-15.69%	-26.34%	-46.01%	-34.95%	-103.43%	-24.01%	-133.73%	-110.4%	-93.64%
Debt / Equity	-	-	-	-	0.13x	0.18x	0.17x	0.09x	0.12x	0.11x
Interest Coverage	-4951.81x	-3385.22x	-40047.43x	-51335.96x	-266983.11x	-20435.13x	-	-	-	-
FCF Conversion	0.14x	0.80x	0.80x	0.94x	1.84x	0.71x	0.11x	0.77x	0.90x	0.77x
Revenue Growth	3.58%	12.68%	-3.93%	-6.53%	28.69%	7.57%	162.14%	-71.71%	1.42%	-1.92%

Revenue by Segment

	2020	2021	2025
ClinicalLabMember	2.92M	3.08M	-
ClinicalLabMember Growth	-	5.29%	-
PhysiciansOfficeMember	2.19M	2.8M	-
PhysiciansOfficeMember Growth	-	27.61%	-
OverthecounterMember	-	766K	-
OverthecounterMember Growth	-	-	-
ContractManufacturingMember	305.76K	552K	-
ContractManufacturingMember Growth	-	80.53%	-
LabSuppliesMember	-	3K	-
LabSuppliesMember Growth	-	-	-
OTCMember	1.27M	-	-
OTCMember Growth	-	-	-

Revenue by Geography

	2020	2021	2025
Asia	-	-	1.72M
Asia Growth	-	-	-
North America	-	-	1.66M
North America Growth	-	-	-
Europe	-	-	1.3M
Europe Growth	-	-	-
Middle East	-	-	630K
Middle East Growth	-	-	-
South America	-	-	8K
South America Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Biomerica, Inc. (BMRA) reported $4.5M in revenue for fiscal year 2025. This represents a 27% decrease from $6.1M in 2012.

Biomerica, Inc. (BMRA) saw revenue decline by 1.9% over the past year.

Biomerica, Inc. (BMRA) reported a net loss of $4.0M for fiscal year 2025.

Dividend & Returns

Biomerica, Inc. (BMRA) has a return on equity (ROE) of -93.0%. Negative ROE indicates the company is unprofitable.

Biomerica, Inc. (BMRA) had negative free cash flow of $2.9M in fiscal year 2025, likely due to heavy capital investments.